These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 10845730

  • 1. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
    Betts T, Waegemans T, Crawford P.
    Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of levetiracetam: a review of three pivotal clinical trials.
    Privitera M.
    Epilepsia; 2001 Mar; 42 Suppl 4():31-5. PubMed ID: 11564123
    [Abstract] [Full Text] [Related]

  • 3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B, Hemdal P, Privitera MD.
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
    Ben-Menachem E, Falter U.
    Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
    [Abstract] [Full Text] [Related]

  • 5. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, Zhao ZX, Lv CZ.
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG, Berkovic SF, Black AB, Danta G, Hiersemenzel R, Schapel GJ, Vajda FJ.
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
    Piña-Garza JE, Nordli DR, Rating D, Yang H, Schiemann-Delgado J, Duncan B, Levetiracetam N01009 Study Group.
    Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
    [Abstract] [Full Text] [Related]

  • 10. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, Weber AM, Stroink H, Geerts Y, Geerts AT, Brouwer OF.
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [Abstract] [Full Text] [Related]

  • 11. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
    Steinhoff BJ, Trinka E, Wieser HG, DACH-LEV Study Group.
    Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
    [Abstract] [Full Text] [Related]

  • 12. Assessment of a dose-response relationship of levetiracetam.
    Meencke HJ, Buyle S.
    Eur J Neurol; 2006 Sep; 13(9):942-6. PubMed ID: 16930358
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges.
    Stodieck S, Steinhoff BJ, Kolmsee S, van Rijckevorsel K.
    Seizure; 2001 Dec; 10(8):583-7. PubMed ID: 11792161
    [Abstract] [Full Text] [Related]

  • 15. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, Stockis A.
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [Abstract] [Full Text] [Related]

  • 16. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
    Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P.
    Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
    Grant R, Shorvon SD.
    Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
    [Abstract] [Full Text] [Related]

  • 18. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
    Genton P, Sadzot B, Fejerman N, Peltola J, Despland PA, Steinhoff B, Rektor I, Wroe S, Maubrey MC, Vandervelden C, van Hammée G, Schlit AF, van Paesschen W.
    Acta Neurol Scand; 2006 Jun; 113(6):387-94. PubMed ID: 16674605
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
    Chung S, Ceja H, Gawłowicz J, Avakyan G, McShea C, Schiemann J, Lu S.
    Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.